Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fibrinogen Clear all
Completed No phase listed Observational

Pharmacodynamics of CNP During Growth Hormone Treatment

NCT01504802
View directory record Official record
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

The Fibrin Patch Soft Tissue Study

NCT00658723
View directory record Official record
Conditions
Hemostasis
Interventions
Fibrin Pad, SURGICEL™
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

NCT01207908
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
IGF-1
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
View directory record Official record
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma

NCT01536496
View directory record Official record
Conditions
Acute Coagulopathy
Interventions
Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Biological
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

The Fibrin Pad Cardiovascular Study

NCT01681030
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
EVARREST™, Topical hemostat, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

NCT00004419
View directory record Official record
Conditions
Insulin Resistance, Hyperglycemia
Interventions
insulin-like growth factor I
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
14 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

NCT01977456
View directory record Official record
Conditions
Stroke, Brain Infarction
Interventions
Eptifibatide
Drug
Lead sponsor
Arthur Pancioli
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Edgewood, Kentucky • Florence, Kentucky • Fort Thomas, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 19, 2026, 6:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

PS-002 for the Treatment of IgA Nephropathy in Adults

NCT07182227
View directory record Official record
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
PS-002
Genetic
Lead sponsor
Purespring Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 6:42 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery

NCT03064152
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Rotational Thromboelastometry
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

NCT01575756
View directory record Official record
Conditions
Congenital Fibrinogen Deficiency, Afibrinogenemia
Interventions
Octafibrin, Haemocomplettan® P or RiaSTAPTM
Biological
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 19, 2026, 6:42 AM EDT
Terminated Phase 3 Interventional

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

NCT00300196
View directory record Official record
Conditions
Stroke, Cerebral Ischemia, Brain Infarction
Interventions
Ancrod (Viprinex), Placebo
Biological · Drug
Lead sponsor
Neurobiological Technologies
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
39
States / cities
Chico, California • Fresno, California • La Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

NCT00600886
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 6:42 AM EDT
Not listed No phase listed Observational

Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation

NCT00005105
View directory record Official record
Conditions
Intrauterine Growth Retardation
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Months to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study

NCT00871455
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Baclofen
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 19, 2026, 6:42 AM EDT
Enrolling by invitation Phase 2 Interventional

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827
View directory record Official record
Conditions
Age Related Macular Degeneration (AMD)
Interventions
GT005
Genetic
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

NCT01731938
View directory record Official record
Conditions
Soft Tissue Surgical Bleeding
Interventions
Fibrin Sealant (FS) Grifols, Surgicel®
Biological · Device
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
Not listed
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Florence, Alabama • Pasadena, California • Bridgeport, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

Open Label Use Of RiaStap During Aortic Reconstruction

NCT01300286
View directory record Official record
Conditions
Coagulopathic Bleeding
Interventions
RiaSTAP
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2014 · Synced Oct 19, 2026, 6:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

NCT06261580
View directory record Official record
Conditions
Healthy
Interventions
TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen
Diagnostic Test
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Oakland, California • Maywood, Illinois • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

The Fibrin Pad CV Phase III Study

NCT02040428
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
EVARREST™ Fibrin Sealant Patch, Topical hemostat
Biological
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 19, 2026, 6:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of Novel Point of Care Coagulation System in Pregnant Women

NCT04301193
View directory record Official record
Conditions
Hemorrhage, Coagulation Delay
Interventions
Quantra Analyzer
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 19, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

NCT01283321
View directory record Official record
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 19, 2026, 6:42 AM EDT
Recruiting Not applicable Interventional

Platelet-Rich Fibrinogen in Extraction Socket Healing of the Aged

NCT06943846
View directory record Official record
Conditions
Edentulism
Interventions
Platelet-rich fibrin (PRF)
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
14 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

NCT02281500
View directory record Official record
Conditions
Congenital Afibrinogenemia
Interventions
Human Plasma-Derived Fibrinogen Concentrate
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
Up to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 19, 2026, 6:42 AM EDT